Positive Outcomes in ALS Treatment Presented by BrainStorm
Recent studies indicate encouraging signs for Amyotrophic Lateral Sclerosis (ALS) patients treated with NurOwn®. This innovative approach is being showcasing by BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) at a significant meeting focused on ALS research.
Understanding NurOwn® and Its Impact
NurOwn®, an investigational treatment platform, harnesses the patient's own mesenchymal stem cells to deliver neurotrophic factors, aiming to support the survival and function of neurons. This treatment protocol shows potential to significantly alter the standard care landscape for ALS, a condition that currently lacks effective options.
Long-Term Benefits Observed
At a recent virtual meeting, BrainStorm presented findings from their Expanded Access Program (EAP) involving ALS patients treated with NurOwn®. Data presented indicated that 9 out of 10 participants remained alive at the last follow-up point, suggesting a substantial long-term survival benefit when compared to a matched control group.
Measuring Neurodegeneration
Along with survival benefits, neurofilament light (NfL) levels, a critical biomarker for neurodegeneration, were monitored. Patients receiving NurOwn demonstrated stabilization in NfL levels, contrasting with rising levels observed in those who initially received a placebo treatment during earlier studies.
Design of Phase 3b Clinical Trial
In conjunction with the EAP results, BrainStorm is poised to advance to a Phase 3b trial, enrolling approximately 200 participants. This trial will evaluate the efficacy of NurOwn against a placebo over a 24-week period, followed by an open-label phase where all participants will receive NurOwn treatment.
Trial Design and Objectives
The entry criteria focus on early-stage ALS patients, with specific conditions documented to ensure that participants are suitable candidates. The ultimate goal is to verify the positive effects observed in earlier stages of clinical development and to gather robust data for regulatory review.
Clinical Assessments and Endpoint Goals
Among other measurements, the trial will utilize the ALS Functional Rating Scale-Revised (ALSFRS-R) as a primary endpoint to assess patient progress. Additional assessments will include survival rates, hand-held dynamometry results, and other relevant metrics that collectively provide insight into patient health during treatment.
Company’s Commitment to ALS Research
BrainStorm's dedicated efforts towards ALS treatment extend beyond the current trial protocols. The company emphasizes their commitment through extensive preclinical research and ongoing clinical studies. Their NurOwn technology not only aims to improve treatment outcomes but also seeks to enhance understanding of the underlying disease pathology.
Regulatory Path Eased by FDA Collaboration
The collaboration with the U.S. FDA on Special Protocol Assessments marks a pivotal point for the future of NurOwn®. This agreement lays the groundwork for expedited regulatory processes, facilitating the possible approval of this critical treatment option for ALS patients.
Looking Toward the Future
As BrainStorm prepares for the upcoming trial phases, they remain committed to transparency, engaging with the ALS community, and sharing insights gathered throughout their research. They anticipate ongoing collaboration with stakeholders and will continue to provide updates as new findings emerge.
For more information on NurOwn® and BrainStorm Cell Therapeutics, interested parties can access resources available to the research community and patients aiming to stay informed about treatment advancements.
Frequently Asked Questions
What is NurOwn®?
NurOwn® is a cellular therapy that uses a patient's own stem cells to deliver neurotrophic factors targeting neurodegenerative diseases.
What were the results from the Expanded Access Program?
The EAP showed significant long-term survival benefits with 9 out of 10 participants alive at their last visit, along with a stabilization of critical biomarkers.
How many participants will be in the Phase 3b trial?
Up to approximately 200 participants are expected to enroll in the Phase 3b clinical trial evaluating NurOwn® against placebo.
What are the major goals of the upcoming trial?
The primary goal is to assess efficiency and safety as indicated by changes in the ALSFRS-R scale and other health metrics after treatment.
How does BrainStorm engage with the ALS community?
BrainStorm actively shares research findings, collaborates with regulatory bodies, and remains in communication with patients and stakeholders to provide updates on their progress.
